Want to see HK:1696 full AI Analyst Report?
Top Page
Sisram Medical Ltd.
(1696)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$2.00
▼(-48.32% Downside)
Action:Reiterated
Date:08/29/26
The score is primarily driven by mixed financial performance—strong balance-sheet safety but pressured profitability and weakened 2025 cash generation. Valuation is attractive (low P/E and solid yield), but the technical picture remains weak with a negative MACD and price below key longer-term moving averages.
Positive Factors
Conservative balance sheet
Very low leverage and a growing equity base reduce financial risk and preserve flexibility for investment, product development, and market expansion. This conservative funding structure should help Sisram withstand periods of weaker profitability without relying heavily on refinancing or additional borrowing.
Negative Factors
Sustained margin compression
The significant decline in net margin shows that revenue growth is currently converting into less bottom-line profit than in earlier periods. If weaker profitability persists, Sisram may have less capacity to fund innovation, sales expansion, and shareholder returns from internally generated earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a growing equity base reduce financial risk and preserve flexibility for investment, product development, and market expansion. This conservative funding structure should help Sisram withstand periods of weaker profitability without relying heavily on refinancing or additional borrowing.
Read all positive factors
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$969.47M
Dividend Yield4.69%
Average Volume (3M)294.42K
Price to Earnings (P/E)10.6
Beta (1Y)1.10
Revenue Growth4.57%
EPS Growth-24.35%
CountryHK
Employees1,043
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding468,343,080
10 Day Avg. Volume332,256
30 Day Avg. Volume294,418
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.66
Revenue Forecast (FY)HK$3.17B
Sisram Medical Ltd. Business Overview & Revenue Model
Company Description
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops...
How the Company Makes Money
Sisram Medical makes money primarily by selling medical aesthetic systems (capital equipment) to clinics, hospitals, and aesthetic service providers, and by generating recurring revenue from products and services tied to its installed base. Key re...
Sisram Medical Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
82
Very Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 371.29M | 365.35M | 349.11M | 359.29M | 354.48M | 294.29M |
| Gross Profit | 213.02M | 215.14M | 216.68M | 219.53M | 202.23M | 166.86M |
| EBITDA | 34.37M | 38.22M | 38.91M | 53.43M | 58.38M | 55.96M |
| Net Income | 11.44M | 19.02M | 25.13M | 31.50M | 40.17M | 31.25M |
Balance Sheet | ||||||
| Total Assets | 676.03M | 657.17M | 627.26M | 613.50M | 555.60M | 530.13M |
| Cash, Cash Equivalents and Short-Term Investments | 77.27M | 70.96M | 71.98M | 70.60M | 91.49M | 157.96M |
| Total Debt | 78.87M | 51.75M | 43.20M | 44.68M | 41.34M | 41.62M |
| Total Liabilities | 174.81M | 153.55M | 142.47M | 143.98M | 123.38M | 126.51M |
| Stockholders Equity | 474.80M | 479.79M | 464.03M | 452.31M | 430.87M | 402.18M |
Cash Flow | ||||||
| Free Cash Flow | -3.29M | 6.82M | 30.38M | 35.37M | -42.28M | 29.41M |
| Operating Cash Flow | -2.74M | 9.40M | 33.08M | 43.94M | 22.04M | 32.38M |
| Investing Cash Flow | -2.14M | -1.70M | -6.59M | -32.99M | -52.11M | -46.77M |
| Financing Cash Flow | 16.72M | -10.92M | -16.11M | -20.97M | -17.85M | 55.78M |
Sisram Medical Ltd. Technical Analysis
Negative
3.87
Price Trends
2.18
Negative
2.40
Negative
3.12
Negative
Market Momentum
-0.06
Negative
45.71
Neutral
32.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 3.87 is above the 20-day moving average (MA) of 2.06, above the 50-day MA of 2.18, and above the 200-day MA of 3.12, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 45.71 is Neutral, neither overbought nor oversold. The STOCH value of 32.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.
Sisram Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$669.19M | 7.44 | 4.52% | 6.63% | -5.14% | -22.72% | |
63 Neutral | HK$969.47M | 10.58 | 2.40% | 4.69% | 4.57% | -24.35% | |
57 Neutral | HK$371.62M | 18.52 | 2.07% | 1.52% | 14.04% | -49.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$3.43B | -20.49 | -7.65% | ― | 21.23% | 36.89% | |
45 Neutral | HK$575.52M | -1.00 | -28.24% | ― | -38.15% | 25.70% | |
34 Underperform | HK$130.46M | -1.40 | -22.16% | 2.02% | -28.07% | 47.54% |
* Healthcare Sector Average
HK:1696
Sisram Medical Ltd.
2.04
-3.97
-66.04%
HK:9996
Peijia Medical Ltd.
4.85
-2.69
-35.68%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.06
-0.07
-54.62%
HK:2407
Gaush Meditech Ltd.
4.50
-4.35
-49.15%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.21
-2.67
-68.81%
HK:6118
Austar Lifesciences Ltd.
0.70
-0.51
-42.15%
Sisram Medical Ltd. Corporate Events
Sisram Medical Sets 2025 Final Dividend and Details Israeli Withholding Tax
Sep 4, 2026
Sisram Medical Ltd. has declared a final ordinary cash dividend of HKD 0.095 per share for the financial year ended 31 December 2025, with an ex-dividend date of 26 August 2026, record date of 27 August 2026, and payment scheduled for 11 September...
Sisram Medical Grows Revenue but Profit Slides in First-Half 2026
Aug 19, 2026
Sisram Medical reported first-half 2026 revenue of US$171.4 million, up 3.6% year on year, driven by a 16.7% rise in international market sales and a 54.2% surge in injectables revenue. Medical aesthetics revenue outside North America grew 7.2% to...
Sisram Medical Sets Record Date and Tax Terms for 2025 Final Dividend
Aug 13, 2026
Sisram Medical has declared a final dividend of HK$0.095 per share for the financial year ended 31 December 2025, payable on or around 9 September 2026 to shareholders on the register as of 27 August 2026. Investors must ensure share transfers are...
Sisram Medical Sets Final 2025 Dividend and Clarifies 20% Israeli Withholding Tax
Aug 13, 2026
Sisram Medical has declared a final ordinary cash dividend of HKD 0.095 per share for the financial year ended 31 December 2025, with an ex-dividend date of 26 August 2026, a record date of 27 August 2026, and payment scheduled for 9 September 202...
Sisram Medical Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 5, 2026
Sisram Medical Ltd. has scheduled a board meeting for 19 August 2026 to review and approve its interim financial results for the six months ended 30 June 2026. The board will also consider declaring an interim dividend, signaling potential shareho...
Sisram Medical Wins Shareholder Backing for New Supply Framework with Fosun Unit
Aug 3, 2026
Sisram Medical Ltd. has secured shareholder approval at its August 3, 2026 extraordinary general meeting for a new supply framework agreement between its subsidiary Sisram Medical HK Limited and Fosun Wanbang (Jiangsu) Health Development Co., Ltd....
Sisram Medical Flags Interim Loss Despite Revenue Growth
Aug 3, 2026
Sisram Medical has warned that it expects to swing to a loss attributable to shareholders of between US$0.9 million and US$1.4 million for the six months ended June 30, 2026, compared with a profit of US$6.4 million a year earlier. Revenue is stil...
Sisram Medical Revamps DAXXIFY China Deal With Connected Fosun Unit
Jul 10, 2026
Sisram Medical’s Tianjin unit has signed a new sublicense agreement and new promotional services agreements with connected party Fosun Wanbang (Jiangsu) to commercialize DaxibotulinumtoxinA-lanm, marketed as 达希斐 and DAXX...
Sisram Medical shareholders approve all AGM resolutions, renew buyback and issuance mandates
Jun 24, 2026
Sisram Medical Ltd. reported that all resolutions put to shareholders at its annual general meeting on 24 June 2026 were approved by poll, including the receipt of its 2025 audited financial statements and the re-election of key executive and non-...
Sisram Medical Calls EGM to Approve New Supply Framework Agreement
Jun 23, 2026
Sisram Medical Ltd. has called an extraordinary general meeting in Hong Kong on 3 August 2026 for shareholders to vote on approving and ratifying a new supply framework agreement between its subsidiary Sisram Medical HK Limited and Fosun Wanbang (...
Sisram Medical delays dispatch of circular on new supply framework agreement
Jun 12, 2026
Sisram Medical Ltd. has announced a delay in sending to shareholders a circular detailing its new supply framework agreement and related proposed annual caps. The document, which will also contain opinions from an independent board committee and a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.